Text Size

Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11

This study has been completed.
Sponsor:
Collaborator:
New York MDRU
Information provided by:
National Institute on Drug Abuse (NIDA)
ClinicalTrials.gov Identifier:
NCT00015301
First received: April 18, 2001
Last updated: June 23, 2005
Last verified: December 2002
History of Changes
  Purpose

The purpose of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.


Condition Intervention Phase
Cocaine-Related Disorders
Substance-Related Disorders
 Drug: Methylphenidate
 Phase 4

Study Type: Interventional
Study Design: Masking: Double-Blind
Primary Purpose: Diagnostic
Official Title: Methylphenidate Raclopride PET Test

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by National Institute on Drug Abuse (NIDA):

Primary Outcome Measures:
  • Dopamine receptor availability

Estimated Enrollment: 0
Detailed Description:

The objective of this study is to evaluate PET methodology to study in vivo synaptic dopamine release.

  Eligibility

Ages Eligible for Study:   18 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

Healthy normals

Exclusion Criteria:

History of head trauma or loss of consciousness. Significant medical history. History of seizures.

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00015301

Locations
United States, New York
New York MDRU
New York, New York, United States, 10010
Sponsors and Collaborators
National Institute on Drug Abuse (NIDA)
New York MDRU
Investigators
Principal Investigator: John Rotrosen, M.D. New York MDRU
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00015301     History of Changes
Other Study ID Numbers: NIDA-5-0013-11, Y01-5-0013-11
Study First Received: April 18, 2001
Last Updated: June 23, 2005
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Methylphenidate
Raclopride
Dopamine Uptake Inhibitors
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
 Neurotransmitter Uptake Inhibitors
Physiological Effects of Drugs
Central Nervous System Stimulants
Central Nervous System Agents
Therapeutic Uses
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Psychotropic Drugs
Dopamine Antagonists

ClinicalTrials.gov processed this record on May 23, 2013